KRAS and neoplasm: The molecular signaling landscape also impacts tumor formation, as evidenced by PTENshRNA alone and in combination with KRAS mutation developing more aggressive peritoneal disease as compared to PTENshRNA in combination with p53 mutation or activation of AKT.